Olsar Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olsar Plus combines the ARB olmesartan medoxomil with the diuretic hydrochlorothiazide, acting on the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps reduce systolic and diastolic blood‑pressure readings.
• Heart failure with reduced ejection fraction: supports fluid removal and blood‑pressure control.
• Diabetic nephropathy in patients with hypertension and proteinuria: slows renal function decline by lowering intravascular pressure.
• Chronic vascular risk management for patients at high cardiovascular risk including stroke and myocardial infarction risk.
• Target to achieve blood‑pressure goals as recommended by clinical guidelines for hypertensive patients with comor ‑ com ‑ ​  

• Olmesartan medoxomil blocks the angiotensin II type 1 (AT‑1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined effect produces a synergistic reduction in systemic vascular resistance and blood‑volume‑related pressure, helping to control hypertension.

Side effects may arise from either component of Olsar Plus.

Common Side Effects

• Dizziness.
• Headache.
• Fatigue.
• Increased urination.
• Electrolyte disturbances (e.g., low potassium).
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension.
• Acute kidney injury.
• Hyperkalemia.
• Angio‑ema.
• Liver enzyme elevation.
• Blood‑cell abnormalities (e.g., neutropenia).

When prescribing Olsar Plus, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor function regularly.
• Hepatic impairment: use with caution; monitor liver tests.
• Electrolyte balance: check potassium and sodium levels periodically.
• Pregnancy: avoid use, especially in the second and third trimesters.
• Concomitant NSAIDs: increase risk of renal dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olsar Plus may interact with several medicines that affect blood pressure, electrolytes, or renal function.

Major Interactions (Avoid)

• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalaemia.
• Aliskiren (in diabetic patients): heightened risk of renal impairment.
• ACE inhibitors or other ARBs: additive hypotensive effect.

Moderate Interaction Monitor Closely

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect kidney function.
• Lithium: increased lithium levels, risk of toxicity.
• Antidiabetic drugs: enhanced glucose‑lowering effect, may need dose adjustment.